Melphalan Flufenamide

DRUG2 trials

Sponsors

Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S, Oncopeptides AB

Conditions

Relapsed and/or Refractory Multiple MyelomaRelapsing Remitting Multiple Sclerosis

Phase 2

NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY

RecruitingCTIS2024-515470-26-00

Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et SRelapsing Remitting Multiple Sclerosis

Start: 2024-10-31Target: 90Updated: 2025-11-17

Unknown Phase

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

Oncopeptides ABRelapsed and/or Refractory Multiple Myeloma

Updated: 2021-03-18